<DOC>
	<DOCNO>NCT01466647</DOCNO>
	<brief_summary>This open single-center , explorative , Phase I pilot dose finding study include patient treat AXL1717 addition standard chemotherapy gemcitabine HCL carboplatin .</brief_summary>
	<brief_title>A Study IGF-1R Inhibitor AXL1717 Combination With Gemcitabine HCL Carboplatin Treat Non-small-cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Open single-center , explorative , Phase I pilot study include patient treat AXL1717 addition standard chemotherapy gemcitabine HCL carboplatin . Patients treat within study 2 treatment cycle 3 week . Survival data obtain . Tumor assessment conduct baseline end study period . Concomitant supportive therapy allow .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . At least 18 year age . 2 . Histologically cytologically confirm diagnosis locally advance , metastatic squamous nonsmallcell lung cancer ( stage IIIB IV ) schedule treatment cytotoxic chemotherapy ( Gemcitabine HCL/Carboplatin ) 3 . Preserved major organ function , i.e : BLeukocyte count ≥ 3.0 x 109/L BNeutrophil count ≥ 1.5 x 109/L BPlatelet count ≥ 75 x109/L BHaemoglobin ≥ 100 g/L ( transfusion allow ) PTotal bilirubin level ≤ 1.5 time upper institutional limit `` normal '' ( i.e . reference ) range PASAT PALAT ≤ 2.5 time upper institutional limit `` normal '' range , ≤5 time liver metastasis document PCreatinine ≤ 1.5 time upper institutional limit `` normal '' range 12lead ECG normal tracing ; clinically nonsignificant change require medical intervention 4 . Signed write informed consent . The presence follow criterion exclude patient participate study : Ongoing infection major recent ongoing disease , accord investigator , pose unacceptable risk patient Grade 3 high constipation within past 28 day grade 2 constipation within past 14 day randomization . ( Patients grade 2 constipation within past 14 day could rescreened constipation decrease ≤ grade 1 optimal management constipation . ) Known malignancy Central Nervous System ( CNS ) Disease dementia neuropathy grade 1 Other active malignancy previous 3 year Major surgical procedure within 4 week Prior antitumor therapy apart radiation therapy Women Of Child Bearing Potential ( WOCBP ) For purpose study , WOCBP include female experienced menarche postmenopausal . Post menopause define : Amenorrhea ≥ 12 consecutive month without another cause Pregnancy lactation Current participation interventional clinical trial Performance status &gt; ECOG 2 optimization analgesic Life expectancy le 3 month Contraindications investigational product , e.g . know suspected hypersensitivity . Lack suitability participation trial , reason , judge Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>NSCLC</keyword>
</DOC>